The DOI matches its Crossref record; 484 of the 484 references it cites were found in a registry or an index.
The Phosphoinositide 3-Kinase Pathway in Human Cancer: Genetic Alterations and Therapeutic Implications
Open accessAbstract
The phosphoinositide 3-kinase (PI3K) pathway is frequently activated in human cancer and represents an attractive target for therapies based on small molecule inhibitors. PI3K isoforms play an essential role in the signal transduction events activated by cell surface receptors including receptor tyrosine kinases (RTKs) and G-protein-coupled receptors (GPCRs). There are eight known PI3K isoforms in humans, which have been subdivided into three classes (I-III). Therefore PI3Ks show considerable diversity and it remains unclear which kinases in this family should be targeted in cancer. The class I(A) of PI3K comprises the p110alpha, p110beta and p110delta isoforms, which associate with activated RTKs. In human cancer, recent reports have described activating mutations in the PIK3CA gene encoding p110alpha, and inactivating mutations in the phosphatase and tensin homologue (PTEN) gene, a tumour suppressor and antagonist of the PI3K pathway. The PIK3CA mutations described in cancer constitutively activate p110alpha and, when expressed in cells drive oncogenic transformation. Moreover, these mutations cause the constitutive activation of downstream signaling molecules such as Akt/protein kinase B (PKB), mammalian target of rapamycin (mTOR) and ribosomal protein S6 kinase (S6K) that is commonly observed in cancer cells. In addition to p110alpha, the other isoforms of the PI3K family may also play a role in human cancer, although their individual functions remain to be precisely identified. In this review we will discuss the evidence implicating individual PI3K isoforms in human cancer and their potential as drug targets in this context.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Items 401–484 of 484
PTEN tumour suppressor is linked to the cell cycle control through the retinoblastoma protein
Paramio, J. M., Navarro, M., Segrelles, C., Gómez‐Casero, E., & Jorcano, J. L. (1999) · Oncogene · doi:10.1038/sj.onc.1203151 · Cited by 129
Hypoxia inducible factor-1: a novel target for cancer therapy
Belozerov, V. E., & Meir, E. G. V. (2005) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000180116.85912.69 · Cited by 128
Possible dominant-negative mutation of the SHIP gene in acute myeloid leukemia
Luo, J.-M., Yoshida, H., Komura, S., Ohishi, N., Pan, L., Shigeno, K., Hanamura, I., Miura, K., Iida, S., Ueda, R., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2402725 · Cited by 127
Hu, L., Hofmann, J., Holash, J. A., Yancopoulos, G. D., Sood, A. K., & Jaffe, R. B. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0910 · Cited by 127
Panayotou, G., Bax, B. D., Gout, I. T., Federwisch, M., Wroblowski, B., Dhand, R., Fry, M., Blundell, T. L., Wollmer, A., & Waterfield, M. D. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05524.x · Cited by 126
Ohmichi, M., Decker, S. J., & Saltiel, A. R. (1992) · Neuron · doi:10.1016/0896-6273(92)90039-g · Cited by 126
Li, Y. M., Zhou, B. P., Deng, J., Pan, Y., Hay, N., & Hung, M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-1284 · Cited by 124
Inukai, K., Anai, M., van Breda, E., Hosaka, T., Katagiri, H., Funaki, M., Fukushima, Y., Ogihara, T., Yazaki, Y., Kikuchi, M., et al. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.10.5317 · Cited by 124
Abdul‐Ghani, R., Serra, V., Győrffy, B., Jürchott, K., Solf, A., Dietel, M., & Schäfer, R. (2005) · Oncogene · doi:10.1038/sj.onc.1209201 · Cited by 122
Liang, K., Jin, W., Knuefermann, C., Schmidt, M., Mills, G. B., Ang, K. K., Milas, L., & Fan, Z. (2003) · PubMed · Cited by 122
Hooshmand-Rad, R., Claesson, L., Wennström, S., Yokote, K., Siegbahn, A., & Heldin, C. (1997) · Experimental Cell Research · doi:10.1006/excr.1997.3636 · Cited by 120
p27Kip1 is required for PTEN-induced G1 growth arrest.
GOTTSCHALK, A. R., Basila, D., Wong, M., Dean, N. M., Brandts, C., Stokoe, D., & Haas-Kogan, D. A. (2001) · PubMed · Cited by 119
Redon, R., Muller, D., Caulee, K., Wanherdrick, K., Abecassis, J., & du Manoir, S. (2001) · PubMed · Cited by 118
PIK3CA mutations in advanced ovarian carcinomas
Wang, Y., Helland, Å., Holm, R., Kristensen, G. B., & Børresen‐Dale, A. (2005) · Human Mutation · doi:10.1002/humu.9316 · Cited by 117
Musacchio, A., Cantley, L. C., & Harrison, S. C. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.25.14373 · Cited by 117
In vitro and in vivo antitumor activity of the phosphatidylinositol-3-kinase inhibitor, wortmannin.
Schultz, R. M., Merriman, R. L., Andis, S. L., Bonjouklian, R., Grindey, G. B., Rutherford, P., Gallegos, A. C., Massey, K. L., & Powis, G. (1995) · PubMed · Cited by 113
Akt/PKB Activity Is Required for Ha-Ras-mediated Transformation of Intestinal Epithelial Cells
Sheng, H., Shao, J., & DuBois, R. N. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010093200 · Cited by 108
Reichert, M., Saur, D., Hamacher, R., Schmid, R. M., & Schneider, G. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4484 · Cited by 107
Phosphoinositide 3-kinases as drug targets in cancer
Stephens, L., WILLIAMS, R., & Hawkins, P. T. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.03.002 · Cited by 106
Klippel, A., Escobedo, J. A., Hu, Q., & Williams, L. T. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.9.5560 · Cited by 104
Isolation of full-length ATM cDNA and correction of the ataxia-telangiectasia cellular phenotype
Zhang, N., Chen, P., Khanna, K. K., Scott, S. P., Gatei, M. H., Kozlov, S., Watters, D. J., Spring, K. J., Yen, T. J., & Lavin, M. F. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.15.8021 · Cited by 103
Bortul, R., Tazzari, P. L., Cappellini, A., Tabellini, G., Billi, A. M., Bareggi, R., Manzoli, L., Cocco, L., & Martelli, A. M. (2003) · Leukemia · doi:10.1038/sj.leu.2402793 · Cited by 102
Wurmser, A. E., & Emr, S. D. (2002) · The Journal of Cell Biology · doi:10.1083/jcb.200112050 · Cited by 101
The association of insulin-elicited phosphotyrosine proteins with src homology 2 domains.
Lavan, B. E., Kuhné, M. R., Garner, C. W., Anderson, D. M., Reedijk, M., Pawson, T. J., & Lienhard, G. E. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)49958-4 · Cited by 98
Jücker, M., Südel, K. M., Horn, S., Sickel, M. J., Wegner, W., Fiedler, W., & Feldman, R. A. (2002) · Leukemia · doi:10.1038/sj.leu.2402484 · Cited by 97
Akt and Hypoxia-Inducible Factor-1 Independently Enhance Tumor Growth and Angiogenesis
Arsham, A. M., Plas, D. R., Thompson, C. B., & Simon, M. C. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2239 · Cited by 96
Inhibition of Akt survival pathway by a small-molecule inhibitor in human glioblastoma
Koul, D., Shen, R., Bergh, S., Sheng, X., Shishodia, S., LaFortune, T. A., Lu, Y., de Groot, J. F., Mills, G. B., & Yung, W. K. A. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0453 · Cited by 96
Holt, K. H., Olson, A. L., Moye-Rowley, S., & Pessin, J. E. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.1.42-49.1994 · Cited by 95
Tang, T. T.-L., & Lasky, L. A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m302042200 · Cited by 94
Cerone, M. A., Ward, R. J., Londoño‐Vallejo, A., & Autexier, C. (2005) · Cell Cycle · doi:10.4161/cc.4.4.1586 · Cited by 93
Responding to Hypoxia: Lessons From a Model Cell Line
Seta, K. A., Spicer, Z., Yuan, Y., Lü, G., & Millhorn, D. E. (2002) · Science Signaling · doi:10.1126/stke.2002.146.re11 · Cited by 93
Cell transformation by the middle T-antigen of polyoma virus
Ichaso, N., & Dilworth, S. M. (2001) · Oncogene · doi:10.1038/sj.onc.1204859 · Cited by 92
Khalfan, W., & Klionsky, D. J. (2002) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(02)00343-5 · Cited by 90
Kharas, M. G., Deane, J. A., Wong, S., O’Bosky, K. R., Rosenberg, N. E., Witte, O. N., & Fruman, D. A. (2004) · Blood · doi:10.1182/blood-2003-07-2193 · Cited by 89
Peles, E., Lamprecht, R., Ben-Levy, R., Tzahar, E., & Yarden, Y. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)49834-7 · Cited by 87
Jackson, J. G., Kreisberg, J. I., Koterba, A. P., Yee, D., & Brattain, M. G. (2000) · Oncogene · doi:10.1038/sj.onc.1203825 · Cited by 87
O'Gorman, D., McKenna, S. L., McGahon, A. J., Knox, K., & Cotter, T. G. (2000) · Leukemia · doi:10.1038/sj.leu.2401726 · Cited by 86
Toretsky, J. A., Thakar, M., Eskenazi, A. E., & Frantz, C. N. (1999) · PubMed · Cited by 85
Yang, W., Ching, K. A., Tsoukas, C. D., & Berg, L. J. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.387 · Cited by 82
Neri, L. M., Borgatti, P., Tazzari, P. L., Bortul, R., Cappellini, A., Tabellini, G., Bellacosa, A., Capitani, S., & Martelli, A. M. (2003) · PubMed · Cited by 81
Lockyer, P. J., Wennström, S., Kupzig, S., Kanamarlapudi, V., Downward, J., & Cullen, P. J. (1999) · Current Biology · doi:10.1016/s0960-9822(99)80116-x · Cited by 80
Hosoi, Y., Miyachi, H., Matsumoto, Y., Ikehata, H., Komura, J., Ishii, K., Zhao, H.-J., Yoshida, M., Takai, Y., Yamada, S., et al. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19981123)78:5<642::aid-ijc19>3.0.co;2-3 · Cited by 80
Workman, P., Clarke, P. A., Guillard, S., & Raynaud, F. I. (2006) · Nature Biotechnology · doi:10.1038/nbt0706-794 · Cited by 78
Bedogni, B., O’Neill, M. S., Welford, S. M., Bouley, D. M., Giaccia, A. J., Denko, N. C., & Powell, M. B. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3327 · Cited by 78
IRS-1: Auditing the effectiveness of mTOR inhibitors
Easton, J. B., Kurmasheva, R. T., & Houghton, P. J. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.02.027 · Cited by 76
Ono, F., Nakagawa, T., Saito, S., Owada, Y., Sakagami, H., Goto, K., Suzuki, M., Matsuno, S., & Kondo, H. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.13.7731 · Cited by 76
McGlade, C. J., Ellis, C., Reedijk, M., Anderson, D. H., Mbamalu, G., Reith, A. D., Panayotou, G., End, P., Bernstein, A., & Kazlauskas, A. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.3.991 · Cited by 76
Full Oncogenic Activities of v-Src Are Mediated by Multiple Signaling Pathways
Odajima, J., Matsumura, I., Sonoyama, J., Daino, H., Kawasaki, A., Tanaka, H., Inohara, N., Kitamura, T., Downward, J., Nakajima, K., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m001606200 · Cited by 74
Shingu, T., Yamada, K., Hara, N., Moritake, K., Osago, H., Terashima, M., Uemura, T., Yamasaki, T., & Tsuchiya, M. (2003) · PubMed · Cited by 74
Cloning and characterization of a novel class II phosphoinositide 3-kinase containing C2 domain.
Misawa, H., Ohtsubo, M., Copeland, N., Gilbert, D. J., Jenkins, N., & Yoshimura, A. (1998) · Biochemical and Biophysical Research Communications - BBRC · doi:10.1006/bbrc.1998.8294 · Cited by 73
Rottapel, R. K., Turck, C. W., Castéran, N., Liu, X., Birnbaum, D., Pawson, T. J., & Dubreuil, P. C. (1994) · PubMed · Cited by 73
Mutated PI 3-Kinases: Cancer Targets on a Silver Platter
Kang, S., Bader, A. G., Zhao, L., & Vogt, P. K. (2005) · Cell Cycle · doi:10.4161/cc.4.4.1593 · Cited by 72
Stephens, L., Jackson, T., & Hawkins, P. T. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)85317-6 · Cited by 71
Gort, E. H., Groot, A. J., van de Ven, T. L. P. D., van der Groep, P., Verlaan-Klink, I., van Laar, T., van Diest, P. J., van der Wall, E., & Shvarts, A. (2006) · Oncogene · doi:10.1038/sj.onc.1209643 · Cited by 70
Zhang, L., Yang, N., Katsaros, D., Huang, W., Park, J.-W., Fracchioli, S., Vezzani, C., de la Longrais, I. A. R., Yao, W., Rubin, S. C., et al. (2003) · PubMed · Cited by 69
Gire, V., Marshall, C. J., & Wynford‐Thomas, D. (2000) · Oncogene · doi:10.1038/sj.onc.1203544 · Cited by 68
Cpk Is a Novel Class of Drosophila PtdIns 3-Kinase Containing a C2 Domain
Molz, L., Chen, Y.-W., Hirano, M., & Williams, L. T. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.23.13892 · Cited by 67
Inhibition of H-Ras transformation by the PTEN/MMAC1/TEP1 tumor suppressor gene
Tolkacheva, T., & Chan, A. M.-L. (2000) · Oncogene · doi:10.1038/sj.onc.1203331 · Cited by 67
Hara, K., Yonezawa, K., Weng, Q.-P., Kozlowski, M. T., BELHAM, C. M., & Avruch, J. (1998) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)48898-9 · Cited by 67
AGC protein kinase phosphorylation and protein kinase C
Parker, P. J., & Parkinson, S. J. (2001) · Biochemical Society Transactions · doi:10.1042/0300-5127:0290860 · Cited by 65
Brown, R. A., Ho, L. K. F., Weber-Hall, S. J., SHIPLEY, J. M., & Fry, M. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6495 · Cited by 64
Fukui, Y., Saltiel, A. R., & Hanafusa, H. (1991) · PubMed · Cited by 63
Yamamoto, K., Altschuler, D. L., Wood, E. R., Horlick, K., Jacobs, S., & Lapetina, E. G. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)49915-8 · Cited by 62
Westfall, S. D., & Skinner, M. K. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0192 · Cited by 61
MutantPIK3CA-Bearing Colon Cancer Cells Display Increased Metastasis in an Orthotopic Model
Guo, X., Rajput, A., Rose, R., Hauser, J., Beko, A., Kuropatwinski, K. K., LeVea, C., Hoffman, R. M., Brattain, M. G., & Wang, J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0049 · Cited by 60
Hu, P. J., & Schlessinger, J. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.4.2577 · Cited by 59
Reinhold, W. C., Kouros‐Mehr, H., Kohn, K. W., Maunakea, A. K., Lababidi, S., Roschke, A. V., Stover, K., Alexander, J., Pantazis, P., Miller, L. D., et al. (2003) · PubMed · Cited by 57
Geng, L., Tan, J., Himmelfarb, E. A., Schueneman, A. J., Niermann, K. J., Fu, A., Cuneo, K. C., Kesicki, E. A., Treiberg, J., Hayflick, J. S., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3955 · Cited by 53
Preferential killing of PTEN-null myelomas by PI3K inhibitors through Akt pathway
Zhang, J., Choi, Y., Mavromatis, B. H., Lichtenstein, A. K., & Li, W. (2003) · Oncogene · doi:10.1038/sj.onc.1206718 · Cited by 52
Kamikura, D. M., Khoury, H., Maroun, C. R., Naujokas, M. A., & Park, M. (2000) · Molecular and Cellular Biology · doi:10.1128/.20.10.3482-3496.2000 · Cited by 52
PI3 Kinases in Cancer: From Oncogene Artifact to Leading Cancer Target
Zhao, J. J., & Roberts, T. M. (2006) · Science s STKE · doi:10.1126/stke.3652006pe52 · Cited by 51
Gire, V., & Wynford‐Thomas, D. (2000) · Oncogene · doi:10.1038/sj.onc.1203399 · Cited by 49
González-García, A., Garrido, E., Hernández, C., Álvarez, B., Jiménez, C., Cantrell, D. A., Pullen, N., & Carrera, A. C. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m103808200 · Cited by 46
Anderson, K. E., Lipp, P., Bootman, M. D., Ridley, S. H., Coadwell, J., Rönnstrand, L., Lennartsson, J., Holmes, A. B., Painter, G. F., Thuring, J. W., et al. (2000) · Current Biology · doi:10.1016/s0960-9822(00)00794-6 · Cited by 45
Identification of Four Novel Human Phosphoinositide 3-Kinases Defines a Multi-isoform Subfamily
Ho, L. K. F., Liu, D., Rozycka, M., Brown, R. A., & Fry, M. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6747 · Cited by 44
Dey, B. R., Furlanetto, R. W., & Nissley, S. P. (1998) · Gene · doi:10.1016/s0378-1119(98)00045-6 · Cited by 42
Janssen, J. W. G., Schleithoff, L., Bartram, C. R., & Schulz, A. (1998) · Oncogene · doi:10.1038/sj.onc.1201695 · Cited by 39
Phosphoinositide 3-kinase and Forkhead, a switch for cell division
Martínez-Gac, L., Álvarez, B., García, Z., Marqués, M., Arrizabalaga, M., & Carrera, A. C. (2004) · Biochemical Society Transactions · doi:10.1042/bst0320360 · Cited by 37
Yamamoto, K., Lapetina, E. G., & Moxham, C. (1992) · Endocrinology · doi:10.1210/endo.130.3.1311242 · Cited by 36
Cooperative transformation of 32D cells by the combined expression of IRS-1 and V-Ha-Ras
Cristofanelli, B., Valentinis, B., Soddu, S., Rizzo, M. G., Marchetti, A., Bossi, G., Morena, A. R., Dews, M., Baserga, R., & Sacchi, A. (2000) · Oncogene · doi:10.1038/sj.onc.1203664 · Cited by 33
Ignatoski, K. M. W., Livant, D. L., Markwart, S. M., Grewal, N., & Ethier, S. P. (2003) · PubMed · Cited by 31
Hickinson, D. M., Lucocq, J. M., Towler, M. C., Clough, S., James, J., James, S., Downes, C. P., & Ponnambalam, S. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00418-0 · Cited by 23
Using Isoform-Specific Inhibitors to Target Lipid Kinases
Simon, J. A. (2006) · Cell · doi:10.1016/j.cell.2006.05.008 · Cited by 18
(1998) · Pure Amsterdam UMC · doi:10.1002/(sici)1097-0142(19980701)83:1 · Cited by 3
Cited by
PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside
Alzahrani, A. S. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.009 · Cited by 1,054
PI3K/AKT/mTOR Signaling Pathway in Breast Cancer: From Molecular Landscape to Clinical Aspects
Miricescu, D., Totan, A., Stanescu-Spinu, I.-I., Badoiu, S. C., Stefani, C., & Greabu, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010173 · Cited by 845
Gastric cancer—molecular and clinical dimensions
Wadhwa, R., Song, S., Lee, J.-S., Yao, Y., Wei, Q., & Ajani, J. A. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.170 · Cited by 423
Almansour, N. M. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.836417 · Cited by 397
Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review)
NITULESCU, G. M., MARGINA, D., JUZENAS, P., PENG, Q., OLARU, O. T., SALOUSTROS, E., FENGA, C., SPANDIDOS, D. A., LIBRA, M., & TSATSAKIS, A. M. (2016) · International Journal of Oncology · doi:10.3892/ijo.2015.3306 · Cited by 364
Metadata
- Authors
- Arcaro, A., & Guerreiro, A.
- Venue
- Current Genomics
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2007-08-01
- Volume
- 8
- Issue
- 5
- Pages
- 271-306
- ISSN
- 1389-2029 (ISSN-L)
- OpenAlex
- W2024611216
- Cited by
- 269
- References
- 484
- FWCI
- 0.72
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.